A B S T R A C T Human bronchial airways obtained after surgical resection were maintained in tissue culture for Three lines of evidence were found suggesting that mast-cell degranulation increases mucous release from cultured airways. (a) Supernatant fluids from anaphylaxed peripheral human lung that contained 200-400 ng/ml histamine and 400-1,000 U/ml slowreacting substance of anaphylaxis (SRS-A) increased release by 40±18%. (b) The addition of antigen to IgE-sensitized airways led to the release of 26±7% ofthe total histamine and a 36+14% increase in mucous release. (c) Reversed anaphylaxis with anti-IgE antibodies induced a 36±6% release of histamine from the airways and an increase in the release of mucous glycoproteins of 25+9%.
Exogenous histamine added to airways increased mucous glycoprotein release, an effect prevented -by cimetidine, an H-2 antagonist. Selective histamine H-2, but not H-1 agonists increased mucous glycoprotein release, suggesting the possibility that anaphylaxis of airways results in increased mucous glycoprotein release partly through histamine H-2 stimulation. A cholinomimetic agonist, methacholine, increased mucous release; this response was prevented by atropine which alone had no effect. No response to ,/-adrenergic stimulation with either isoproterenol or epinephrine was noted. However, a-adrenergic stimulation with either norepinephrine combined with propranolol or phenylephrine alone resulted in doserelated increases in glycoprotein release. Both aadrenergic and cholinergic stimulation of human tissues induce the formation of guanosine 3',5'-phosphoric acid (cyclic GMP), and 8-bromo cyclic GMP added to the airways led to increased mucous secretion. Thus, it seems likely that neurohormones capable of stimulating cyclic GMP formation in human airways may lead to increased mucous glycoprotein release.
INTRODUCTION
Pathologic examinations of fatal cases of status asthmaticus almost always reveal diffuse secretions of mucus which appear to contribute significantly to the airways obstruction (1) . In less severe asthmatic attacks, mucous secretion probably contributes to the bronchial obstruction but the degree varies. Several investigations in experimental animals in vivo and in vitro have demonstrated that cholinergic, a-adrenergic, and 83-adrenergic stimulation can increase mucous secretion (2) (3) (4) (5) (6) . Only a few in vitro studies of mucous secretion using human lung have been reported and these reports indicate, as analyzed by autoradiographical changes (7) or radiolabeled glycoprotein secretion (8) , that muscarinic stimulation increases mucous synthesis and release. No investigation of the role allergic reactions may play in human or animal mucous secretion by lung tissue has previously been reported, although either immune complexes or anaphylaxis may stimulate rat intestinal goblet cell secretion (9) (10) (11) .
To evaluate the effects of anaphylaxis on the release of mucus, we modified previously reported methods (8, 12) Culture of human airtways. Macroscopically normal portions of human lungs were obtained at surgery for resection of carcinoma. The tumor-free portions of human lung were placed in L-15 carrier medium and transported as (quickly as possible to the laboratory. Airways were identified (2-10 mm in diameter) and carefully dissected. Wherever visible, cartilage and alveolar tissue were cut away from the airway tissue. The usual explants were 2nd to 5th division bronchi. The airways were sectioned into 3 x 5-mm fragments. Two replicate fragments were placed on 5 x 10-mm gel foam pads which were 3.5 mm in height and had previously been affixed to 35-mm tissue culture dishes. The airway cultures were maintained in 2.0 ml of CMRL-1066 wvith bovine insulin (1 ,ug/ml), hydrocortisone hemisuccinate (0.1 ,ug/ml), penicillin (100 ,tg/ml), streptomycin (100 ,g/ml), and amphotericin B (0.5 ,ug/ml). Cultures were maintained at 370C in a controlled atmosphere chamber purged with 45% 02, 50% N2, and 5% CO2 (12) . Histologic analysis of airways maintained in culture for up to 96 h revealed a normal appearing mucosal surface including goblet cells. Submucous glands in these bronchial fragments were present in every section, outnumbered the goblet cells by a considerable margin, and remained histologically normal through at least 48 h. (5, 8), to compare the nondialyzable radiolabeled glycoprotein released from each fragment with the nondialyzable radioactivity released in the control period. This analysis resulted in a consistent ratio from fragment to fragment within each experiment.
The effect of various manipulations on the release of labeled mucous glycoprotein was determined by adding agents to cultures at the beginning of period II. The ratio of the radiolabeled nondialyzable glycoprotein released in period II as compared to period I in these manipulated samples was contrasted with the ratio in matched control samples. Thus, each airway culture provided its own control period, as well as stimulated period, and the effect of each manipulation upon the ratios of period II/period I could be compared with identical, matched controls. All fragments were subjected to identical conditions in period I and period II except that stimulated fragments were incubated with pharmacologic or immunologic reagents during period II. In this manner, the matched control fragments provided a valid reference for statistical comparison. We used 24 individual lungs in all. The mean ratio of period II to period I in control samples was 0.70+0.08 (n = 24) with a range of 0.12 to 1.19. The mean nondialyzable counts per minute per milliliter of period I was 3,739+730 (n = 24) and of period II was 2,233±457.
Passive sensitization ofairwvays. In experiments involving passive sensitization, the airway fragments were incubated in sera rich in IgE antibody directed against ragweed pollen for 2 h at 37°C (13) . The airway preparations were thoroughly washed and placed in culture under the conditions described as period I. Antigen challenge was performed at the onset of period II by adding 0.5 ,ug/ml ragweed antigen E to the culture fluid. In the five experiments with passive anaphylaxis, 26±8% of the total airway histamine was released. The final concentration ofhistamine released into the culture media was 140±67 nglml.
Reversed anaphylaxis of airtways. No special preparation of lung tissue for reversed anaphylaxis was necessary (14) . In the four experiments in which this procedure was followed, a dose response of rabbit antihuman IgE on autologous peripheral lung fragments was determined before challenge of the airway preparations. Optimal concentrations ranged from 1:40 to 1:100. The appropriate optimal concentration of antiIgE was added at the onset of period II and resulted in 36±6% histamine release. Supematant fluids were dialyzed against 6 M urea in 0.005 M phosphate buffer, pH 6.8, and applied to a 1.5 x 100-cm Sepharose 2B column equilibrated in 6 M urea, phosphate buffer. Column was eluted by gravity flow at 1.5 ml/h and 1.4-ml fractions collected.
and challenged with specific antigen as described (13) . Four separate lung supernatant fluids were prepared, each containing 200-400 ng/ml histamine and 400-1,000 U SRS-A/ml. These mediator-rich supernatant fluids (0.5 ml) were added to 1.5 ml of culture media at the onset of period II.
Chromatography. Radiolabeled supematant fluids were analyzed by gel filtration and ion-exchange chromatography. Aliquots of the lung supematant fluid were concentrated (Amicon Corp., Lexington, Mass.), dialyzed against 6 M urea in 0.005 M phosphate, pH 6.8, and applied to a 1.5 x 100-cm Sepharose 2B column previously equilibrated in 6 M urea/ 0.005 M phosphate buffer, pH 6.8. The column was eluted by gravity with a flow rate of 1.5 ml/h. Elution of radiolabeled material (1.4 ml fractions) was monitored by liquid scintillation counting of portions of each fraction. The portions of the elution volume containing radioactively labeled molecules were pooled, concentrated to 1.0 ml, and applied to a 1.5 x 30-cm DEAE-cellulose column equilibrated in 6 M ureal0.005 M phosphate buffer, pH 6.8. The column was washed with 2-column vol of starting buffer followed by a linear salt gradient (4-column vol) from 0 to 1 M NaCl in the starting buffer. The column was run at 20 ml/h and 3.5-ml (Fig. 1) . Two discrete peaks of radioactivity were observed in glucosamine, threonine, or sulfate-labeled material: about 50% of the radioactivity eluted in the void voluime while the other half entered the column and eluted between ferritin and catalase. The void-volume fraction was designated fraco) tion A and the included fraction was designated frac0°t ion B. The portion of radiolabeled glucosamine in- (Fig. 2, top panel) trated, and separately applied to DEAE-cellulose (Fig.  2, lower panels) . Both fractions A and B eluted from the DEAE column in a single peak at 0.2 M NaCl, a pattern entirely concordant with the chromatography of the unfractionated airway supernatant fluid.
Modulation of mucous release. The mucous glycoprotein molecules were labeled equally well with glucosamine, threonine, or Na2SO4. For (Table III) . The relative contribution of histamine H-1 and H-2 (17) stimulation on mucous glycoprotein secretion was analyzed using both receptor antagonists and selective agonists (Fig. 3) . Histamine alone at 100 ,uM significantly increased mucous secretion. The H-2 receptor antagonist, cimetidine (100 ,uM), had no influence on mucous release when studied alone and prevented histamine-induced increases when added with histamine. We were unable to study the effect of H-1 receptor antagonists (either pyrilamine or diphenhydramine, both 100 ,uM) because they increased mucous secretion. The selective H-1 agonist, 2-methylhistamine (100 ,uM) (18), failed to significantly alter mucous glycoprotein release, whereas two separate H-2 agonists, dimaprit and impromidine (19) , Effects of neurohormones. Submucous glands are richly innervated with parasympathetic fibers (20) . Other studies, including several of human lung airways in vitro (7, 8) , have demonstrated that parasympathetic stimulation increases mucous glycoprotein secretion. The cholinergic agonist, methacholine (100 /.M), added in period II caused a 62% increase (n = 10,P < 0.001) above control (Fig. 4) . This increase was blocked by the addition of atropine (100 ,uM) before stimulation with methacholine. Atropine alone had no effect. Thus, muscarinic stimulation results in augmented mucous release.
The effects of adrenergic stimulation of human airways were also examined. The f3-adrenergic agonists, isoproterenol (100 uLM) and epinephrine (100 ,uM), added to airway cultures at the initiation of period II were without significant effect (% change = 33, ni = 2, and 8+1, n = 2, respectively). By contrast, phenylephrine (1-100 ,uM) was found to induce a significant dose-related increase in mucouis secretion (Table IV) . Because these data suggest that aadrenergic stimulation results in increased mucou.s secretion, the effects of norepinephrine, alone and in the presence of the ,B-adrenergic blocking agent propranolol, were examined (Fig. 5 ). Norepinephrine Effect of cyclic ntucleotides. To investigate the potential mechanisms by which anaphylaxis, histamine, and neurohormones influence mucous secretion, we studied the effects of cyclic GMP and cyclic AMP, added at the onset of period II. Dibutyryl cyclic AMP (0.1-50 mM) had no effect on mucous release. However, 8-bromo cyclic GMP (0.01-100 ,uM) consistently increased the release of nondialyzable radiolabeled molecules (Fig. 6) . In three separate experiments, the peak effect was noted at 1 ,uM with a mean increase above control of 34+5.5% (P < 0.05). sulfate into two macromolecules. By Sepharose 2B gel filtration analysis, these molecules filter with apparent molecular weights of >7,000,000 and -400,000. These molecular weights are only approximate since glycoproteins are known to demonstrate anomalous behavior on gel filtration. Radiolabeled glucosamine was incorporated equally into each of these two fractions. Similar molecules have previously been found in expectorated human sputa (21, 22) , as well as by analyses of experimental animal models of mucous secretion (23, 24) . The two macromolecules demonstrated similar charge characteristics on DEAE-cellulose anion exchange chromatography. By nature of the incorporation of glucosamine, threonine, or sulfate into macromolecules synthesized by airway preparations, we conclude, as have others (8, 24) , that the biosynthetically labeled molecules are mucous glycoproteins.
The bronchial airway preparations employed in these experiments contained both submucosal glands and goblet cells. The submucosal gland cells appeared to far outnumber the goblet cells but we cannot differentiate the cellular origin of the biosynthetically labeled molecules. Using an analogous culture system, Reid and co-workers (7, 25) MM 8-BROMO CYCLIC GMP FIGURE 6 The effect of 8-bromo cyclic GMP (0.01-100 ,M) on mucous secretion. The figure presents the mean percent increase above control of the pooled results from three individual lungs, *, P < 0.05. radiolabeled sulfate and sugars may be demonstrated within goblet cells in canine airway epithelial cultures (26 These data indicate that a product derived from degranulated lung mast cells is capable of stimulating mucous secretion. Histamine has previously been suggested as a mucous secretagogue (15) , although other in vitro experiments have been inconsistent with this conclusion (5, 7, 16 ). Histamine ,uM) increased mucous secretion maximally at 100 ,uM. Peripheral human lung contains 10 ,ug of histamine/g wet wt (27) . It might be anticipated that the immunologic release of as little as 20% of total histamine (the mean percent histamine released by allergen-IgE interactions in human lung in vitro) would generate histamine concentrations in the interstitial space around mast cells exceeding 100-1,000 ,mM. The effects of exogenous histamine on mucous secretion could be prevented by H-2 receptor antagonists and reproduced by H-2 agonists. H-1 receptor antagonists could not be studied as they appeared to be stimulatory; however, 2-methylhistamine, an H-1 agonist, was not effective. These data indicate that histamine stimulates mucous secretion by interacting with H-2 receptors.
Asthmatic patients appear to have an array of abnormalities of autonomic responsiveness including reduced 3-adrenergic responses (28, 29) and heightened a-adrenergic (30) and cholinergic responses (31, 32) . It was therefore of interest to examine the effects of the neurohormones which mediate these neurologic functions. The selective B3-adrenergic agonist, isoproterenol, which has previously been shown to have no effect on human airway mucous glycoprotein synthesis (7) and secretion (8) , was also found to be ineffective in the current experiments. By contrast, isoproterenol has been demonstrated to increase tracheal mucous secretion in the cat in vivo (2) . Epinephrine, like isoproterenol, had no effect in our experiments. Norepinephrine alone appeared to produce no significant effect on mucous secretion. However, when the /8-adrenergic actions of norepinephrine were blocked by exposing the airways to propranolol, a dose-related increase in mucous secretion was observed. The possibility that a-adrenergic stimulation might increase mucous secretion was confirmed when the effects of the relatively pure aadrenergic agonist phenylephrine were examined. Phenylephrine induced a dose-related increase in mucous secretion. Therefore, a-adrenergic stimulation of human mucous glands causes increased secretions much as seen in the cat (3). Cholinergic stimulation of muscarinic receptor sites was also found to increase mucous release, as has been previousy reported (5, 7, 8) . Both cholinergic stimulation of human lung in vitro (13) and a-adrenergic agonist infusions into humans in vivo (33) are associated with increased cyclic GMP. Therefore, the observation that exogenously administered cyclic GMP augments mucous secretion in vitro suggests the possibility that elevations in this molecule might be a common pathway for cholinergically and a-adrenergically mediated stimulation of secretion.
Evidence has been presented suggesting that several factors relevant to allergic reaction of human airways may contribute to increased mucous glycoprotein secretion. These factors include the mediators of anaphylaxis generated by human lung undergoing allergic reactions as well as several neurohormones to which asthmatics have been shown to be hyperreac-tive (30) (31) (32) . Therefore, it seemns likely that allergic reactions in human lung initiate responses leading to heightened mucous secretion.
